Skip to content

Immix Biopharma, Inc. IMMX Short-Term Investments

Short-Term Investments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$363M+18.2%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$236.58M-0.4%
Regenxbio logo
RegenxbioRGNX
$135.26M-1.8%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$204.25M+9.9%
Precigen logo
PrecigenPGEN
$48.77M-34.3%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s short-term investments?
Immix Biopharma, Inc. (IMMX) reported short-term investments of $11.33M in Q1 2026.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.